27.08MMarket Cap-2479P/E (TTM)
1.050High1.020Low55.71KVolume1.040Open1.045Pre Close57.48KTurnover0.24%Turnover RatioLossP/E (Static)26.32MShares3.21252wk High0.75P/B23.46MFloat Cap0.94052wk Low--Dividend TTM22.79MShs Float33.340Historical High--Div YieldTTM2.87%Amplitude0.940Historical Low1.031Avg Price1Lot Size
ImmunoPrecise Antibodies Stock Forum
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
loading...
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
Dow Jones· 4 mins ago
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were app...
No comment yet